昂科諾娃治療公司(納斯達克市場代碼：ONTX)獲得了斯托克新聞網分析師的新報道

Equities researchers at StockNews.com began coverage on shares of Onconova Therapeutics (NASDAQ:ONTX – Get Rating) in a research note issued to investors on Tuesday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.

Separately, Noble Financial reiterated a "buy" rating and issued a $11.00 target price on shares of Onconova Therapeutics in a report on Thursday, May 12th.

Get

Onconova Therapeutics

alerts:

Onconova Therapeutics stock opened at $1.30 on Tuesday. Onconova Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.86. The firm has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.67. The company has a market capitalization of $27.16 million, a PE ratio of -1.53 and a beta of 1.61.

Onconova Therapeutics (NASDAQ:ONTX – Get Rating) last posted its earnings results on Wednesday, May 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Onconova Therapeutics had a negative net margin of 6,889.38% and a negative return on equity of 36.41%. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.06 million. During the same quarter last year, the business posted ($0.30) EPS. As a group, research analysts predict that Onconova Therapeutics will post -0.79 earnings per share for the current year.

A hedge fund recently raised its stake in Onconova Therapeutics stock. Renaissance Technologies LLC raised its holdings in Onconova Therapeutics, Inc. (NASDAQ:ONTX – Get Rating) by 140.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 321,743 shares of the biopharmaceutical company's stock after buying an additional 188,116 shares during the period. Renaissance Technologies LLC owned approximately 1.54% of Onconova Therapeutics worth $592,000 as of its most recent SEC filing. 11.53% of the stock is currently owned by hedge funds and other institutional investors.

About Onconova Therapeutics (Get Rating)

Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer.

See Also

• Get a free copy of the StockNews.com research report on Onconova Therapeutics (ONTX)
• Using MarketBeat Market Data Tools To Find Strong Stocks in a Bear Market
• Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
• MarketBeat: Week in Review 6/27 – 7/1
• Accolade Moves Higher But Growth Is Slowing
• ZIM Integrated Shipping Services (ZIM): Don't Miss This Dividend

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.